ClinicalTrials.gg
CompletedNCT06415292Updated Mar 4, 2025Results posted

A Study to Evaluate the Impact of Clascoterone 1% Cream on Skin Barrier Properties in Acne Prone Patients

A Phase 4 interventional study of Winlevi (clascoterone) 1% cream in Acne Vulgaris, sponsored by Sun Pharmaceutical Industries Limited. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-04.

Sponsored by Sun Pharmaceutical Industries Limited · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Nov 2023, registered May 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing clascoterone in Acne Vulgaris — 5 open to participants now, 7 under way, 2 of them phase 3. Clascoterone · Acne Vulgaris.

Enrollment
10th of 19
50 · median 50
Started
2023
with 3 others
Phase 4
7 of 19
1 open now
Registered
11th of 19
by date
Lead sponsor
6 of 19
Sun Pharmaceutical Industries Limited

Among the 19 studies testing clascoterone in Acne Vulgaris, this one is the 10th largest by enrollment, is one of 4 that started in 2023, is one of 7 in phase 4, and was the 11th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

5 of the 19 studies testing clascoterone in Acne Vulgaris are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About clascoterone

Clascoterone: first FDA approval 2020 (WINLEVI), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing clascoterone in Acne Vulgaris, or all of them as a file.
02

Study summary

Acne medications are a common source of facial dryness resulting in skin barrier damage and poor patient compliance. Retinoids and benzoyl peroxide are some of the most frequently prescribed and effective acne medications, however, dryness is an unwanted side effect. A new acne medication, 1% clascoterone, has been placed in a novel vehicle for excellent drug delivery in combination with excellent barrier properties. The barrier properties of 1% clascoterone have never been demonstrated. This study is aimed at better understanding the positive barrier effects of 1% clascoterone.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who self identify as having sensitive acne prone skin.
  2. Female or male subjects 18+ years of age.
  3. Subjects with Fitzpatrick skin types I-VI.
  4. Subject agrees not to introduce any new colored cosmetics (lipsticks, eye shadows, facial foundations, blush, powder) or skin care products during the study.
  5. Subjects must be willing to use only a cleanser and sunscreen on the entire face and no other skin care products.
  6. Subjects must be willing to use the Winlevi study product to designated half face. No other topical acne treatment products on the entire face for the 2 week duration of the study.
  7. Subject has signed an Form in compliance with 21CFR Part 50: "Protection of Human Subjects."
  8. Subject is dependable and able to follow directions and is willing to comply with the schedule of visits.
  9. Subject is in generally good physical and mental health.

Exclusion criteria

Exclusion Criteria:

  1. Any dermatological disorder, which in the investigator's opinion, may interfere with the accurate evaluation of the subject's skin characteristics, except for the conditions associated with sensitive skin.
  2. Subjects who are not willing to use only the assigned study product and nothing else one randomized half face, except for cleanser and sunscreen that must remain unchanged during the study. Moisturizers or topical acne treatment products should not be used during the 2 week study period on either side of the face.
  3. Subjects who do not agree to refrain from direct sun exposure during the study duration.
  4. Subjects who have demonstrated a previous reaction to any of the ingredients of the study products.
  5. Subjects, who are pregnant, breast feeding, or planning a pregnancy.
  6. Subjects with unstable medical disorders.
  7. Subjects who are unwilling or unable to comply with the requirements of the protocol.
  8. Subjects who have history of a psychological illness or condition that would interfere with their ability to understand and follow the requirements of the study.
  9. Subjects who are currently participating in any other clinical study.
  10. Subjects with any planned surgeries and/or invasive medical procedures during the course of the study.
  11. Subjects who currently or frequently use high doses of anti-inflammatory drugs for a defined medication condition. Aspirin use should not exceed 2 tablets (650 mg) per day.
  12. Subjects currently receiving any anticancer, treatments/ medications (e.g., azathioprine, belimumab, cyclophosphamide, Enbrel, Imuran, Humira, mycophenolate mofetil, methotrexate, prednisone, Remicade, Stelara.), or radiation as determined by the initial paperwork.
  13. Subjects with a history of immunosuppression/immune deficiency disorders (including ( infection or AIDS) or currently using immunosuppressive medications (e.g., azathioprine, belimumab, cyclophosphamide, Enbrel, Imuran, Humira, mycophenolate mofetil, methotrexate, prednisone, Remicade, Stelara) and/or radiation as determined by study documentation.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double (Investigator, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Winlevi (clascoterone) 1% treated

    Splitface design- Subjects applied Winlevi (clascoterone) cream 1%, twice daily to the randomized half face following cleansing, every morning and evening.

    Drug: Winlevi (clascoterone) 1% cream

  • No intervention
    Splitface design- No study product

    Splitface design-no study product was applied to the untreated side of the face

Interventions

  • Splitface design- Subjects applied Winlevi (clascoterone) cream 1%, twice daily to the randomized half face following cleansing, every morning and evening.

06

What researchers measure

Primary outcomes

  1. The Primary Endpoint is the Change in Corneometry Reading Between the Two Sides of the Face Treated With Winlevi Versus no Treatment.

    The Corneometer measures skin hydration with a range of 0- 1000 MicroSiemens, where 0 is lowest and 1000 is highest hydration

    Time frame: Week 2

Secondary outcomes

  1. Change in TEWL Reading Between the Two Sides of the Face Treated With Winlevi Versus no Treatment

    The instrument measures trans epidermal water loss (abbreviated as TEWL) which ranges from minimum 0 (no trans epidermal water loss) to maximum 100 (high trans epidermal water loss)

    Time frame: Week 2

07

Results

Posted Mar 4, 2025

Participant flow

Participant flow — Overall Study
MilestoneWinlevi (Clascoterone) 1% Treated
Started50
Winlevi (clascoterone) 1% un-treated side (ut)50
Winlevi (clascoterone) 1% treated side (t)50
Completed49
Not completed1

Outcome measures

PrimaryThe Primary Endpoint is the Change in Corneometry Reading Between the Two Sides of the Face Treated With Winlevi Versus no Treatment.

The Corneometer measures skin hydration with a range of 0- 1000 MicroSiemens, where 0 is lowest and 1000 is highest hydration

Time frame:
Week 2
Reported as:
Mean · microSiemens (μS)
The Primary Endpoint is the Change in Corneometry Reading Between the Two Sides of the Face Treated With Winlevi Versus no Treatment.
microSiemens (μS)Winlevi (Clascoterone) 1% Un-treated Side (UT)Winlevi (Clascoterone) 1% Treated Side (T)
The Primary Endpoint is the Change in Corneometry Reading Between the Two Sides of the Face Treated With Winlevi Versus no Treatment.131.27 ± 42.92113.94 ± 36.61
Statistical analysis
  • Winlevi (Clascoterone) 1% Un-treated Side (UT) · t-test, 2 sided · p = <0.001 (The P-value reported here is the calculated p-value. The p-value theshold for significance was p =0.05)
SecondaryChange in TEWL Reading Between the Two Sides of the Face Treated With Winlevi Versus no Treatment

The instrument measures trans epidermal water loss (abbreviated as TEWL) which ranges from minimum 0 (no trans epidermal water loss) to maximum 100 (high trans epidermal water loss)

Time frame:
Week 2
Reported as:
Mean · g/h/m²
Change in TEWL Reading Between the Two Sides of the Face Treated With Winlevi Versus no Treatment
g/h/m²Winlevi Un-treated Side (UT)Winlevi Treated Side (T)
Change in TEWL Reading Between the Two Sides of the Face Treated With Winlevi Versus no Treatment9.94 ± 2.599.92 ± 2.88

Adverse events

Collected over 2 Weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Winlevi (Clascoterone) 1% Treated0/50 (0%)0/50 (0%)1/50 (2%)
Most frequent other events
Most frequent other events
EventWinlevi (Clascoterone) 1% Treated
Covid 19Respiratory, thoracic and mediastinal disorders1/50

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Winlevi (Clascoterone) 1% Treated
<=18 years0
Between 18 and 65 years50
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Winlevi (Clascoterone) 1% Treated
Female38
Male12
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Winlevi (Clascoterone) 1% Treated
Hispanic1
African Americans19
Caucasians30
08

Study locations

1 site
  • Dermatology Consulting Services, PLLC
    High Point, North Carolina 27262, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Dec 2023, 0 months.

Results were first posted in Mar 2025, 1 year 2 months after primary completion.

Of 45 phase 4 interventional studies under Acne Vulgaris, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 0 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2024
First posted
May 16, 2024
StartActual
Nov 27, 2023
Primary completionActual
Dec 16, 2023
CompletionActual
Dec 16, 2023
Results first posted
Mar 4, 2025
Last update
Mar 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06415292
Responsible party
Sponsor
First posted
May 16, 2024
Start date
Nov 27, 2023
Primary completion
Dec 16, 2023
Completion
Dec 16, 2023
Results posted
Mar 4, 2025
Last update
Mar 4, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clascoterone

Start the discussion